Some nerve pain patients never get the right drug because the medications themselves are mediocre, the doctors prescribing them often lack specialized training in neuropathic pain, and the side effects drive people to quit before a drug even has a fair shot. That is not a fringe opinion. The International Association for the Study of Pain declared 2026 the Global Year for Neuropathic Pain, stating plainly that the condition “often remains underdiagnosed, undertreated, and misunderstood — contributing to avoidable suffering worldwide.” When between 580 and 830 million people globally are affected by neuropathic pain, and the best available drugs fail to produce meaningful relief in more than half of them, the problem is not patient compliance. The problem is systemic. Consider a 62-year-old woman with diabetic peripheral neuropathy. Her primary care doctor starts her on gabapentin. She gets dizzy, gains weight, and feels foggy — side effects that hit more than 20 percent of patients on this drug. After three months of poor relief and worsening cognition, she stops taking it.
Her doctor switches to pregabalin. Same class, same story. A 2025 meta-analysis published in Frontiers in Pain Research found no significant difference in efficacy between gabapentin and pregabalin, the two most-prescribed gabapentinoids. She has now spent half a year on drugs that were statistically unlikely to help her in the first place. She is not unusual. She is the norm. This article examines why the current treatment landscape fails so many nerve pain patients — from the dismal clinical trial numbers to primary care knowledge gaps, the side-effect problem that torpedoes adherence, how the opioid crisis inadvertently made things worse, and what recent research says about the road ahead. For those living with neuropathic pain or caring for someone who does, particularly older adults already managing cognitive decline, understanding these failures is the first step toward advocating for better care.
Table of Contents
- Why Do So Many Nerve Pain Drugs Fail to Provide Relief?
- The Side-Effect Problem That Drives Patients to Quit
- How Primary Care Knowledge Gaps Leave Patients Stranded
- What the Opioid Crisis Changed — and What It Made Worse
- Neuropathic Pain in Underserved Populations — An Invisible Crisis
- Why Combination Therapy Is Underused
- What Current Research Says About the Future
- Conclusion
- Frequently Asked Questions
Why Do So Many Nerve Pain Drugs Fail to Provide Relief?
The short answer is that none of the available drugs work well for most people. According to data compiled by the NeuPSIG (the Neuropathic Pain Special Interest Group of IASP), the Number Needed to Treat for 50 percent pain relief tells a grim story across every drug class. Tricyclic antidepressants like amitriptyline have an NNT of 3.6, meaning roughly one in four patients gets adequate relief. SNRIs such as duloxetine fare worse at 6.4. Gabapentin sits at 7.2, and pregabalin at 7.7. For gabapentin, a doctor must treat approximately seven patients for just one to experience adequate pain reduction. As IASP itself has stated, for any neuropathic pain drug, “the most probable outcome is failure to produce 50% pain relief.” These are not obscure findings buried in academic footnotes. They represent the ceiling of what modern pharmacology offers for neuropathic pain. Fifty to sixty percent of patients get no meaningful relief from current medications.
Only 40 to 50 percent achieve even a 30 percent reduction in pain — a threshold that, it should be said, still leaves a person in considerable discomfort. Compare this to treatments for other chronic conditions. Blood pressure medications routinely hit their targets in well over half of patients on first-line therapy. The gap between what nerve pain drugs promise and what they deliver is not small. It is a chasm. What makes this especially relevant for brain health is the overlap between neuropathic pain and cognitive impairment. Many of these drugs — gabapentinoids, tricyclics, even opioids with an NNT of 4.3 — carry cognitive side effects ranging from brain fog to sedation. For an older adult already managing early-stage dementia or mild cognitive impairment, the tradeoff between partial pain relief and accelerated cognitive decline is a cruel one. A 2025 Lancet Neurology systematic review and meta-analysis re-evaluated both pharmacotherapy and non-invasive neuromodulation for neuropathic pain and confirmed the continued limited efficacy of current treatments, offering little new hope on the drug front.
The Side-Effect Problem That Drives Patients to Quit
Even when a drug offers partial relief, patients frequently abandon treatment because the side effects become unbearable. A 2025 systematic review and meta-analysis examining predictors of prescribing, adherence, and discontinuation confirmed what clinicians already suspected: large proportions of patients discontinue neuropathic pain treatment within six months, regardless of the medication used. this is not noncompliance born of carelessness. It is a rational response to drugs that make daily life harder in new ways. Gabapentin causes dizziness and somnolence in over 20 percent of patients. Pregabalin commonly produces dizziness, somnolence, dry mouth, peripheral edema, and blurred vision. Tricyclic antidepressants carry the risk of cardiotoxicity through anticholinergic effects, which limits their use in elderly patients — the very population most likely to have neuropathic pain.
For someone caring for a spouse with dementia while managing their own diabetic neuropathy, a drug that causes persistent drowsiness and mental fog is not a treatment. It is a different kind of suffering. However, stopping a drug is not the same as failing on it, and this distinction matters. If a patient discontinues gabapentin at 300 milligrams daily due to dizziness, it is possible that a slower titration or a lower maintenance dose might have been tolerable. Outside of specialist pain clinics, this kind of careful dose management often does not happen. Research published in PMC has documented “considerable variation in the correct sequencing of therapeutic classes, initiation of treatment, and achieving therapeutic dosing” in non-specialist settings. The side-effect problem is real, but it is compounded by rushed prescribing and inadequate follow-up. If your physician has never asked you about the specific side effects you are experiencing or discussed dose adjustments before moving to a different drug, you have not yet gotten a fair trial of that medication.
How Primary Care Knowledge Gaps Leave Patients Stranded
Most patients with neuropathic pain are managed entirely in primary care. Only a minority are ever referred to a pain specialist, neurologist, or other clinician with focused expertise in nerve pain diagnosis and treatment. This is not a criticism of primary care physicians, who manage an enormous breadth of conditions. It is a structural reality. According to research published in PAIN Reports, the epidemiology of neuropathic pain in general practice reveals that the condition is frequently under-recognized and undertreated at the point of first contact. The knowledge gap manifests in several concrete ways. A patient with burning, shooting pain in the feet might receive a diagnosis of “peripheral neuropathy” without the more specific classification of whether the pain is neuropathic, nociceptive, or mixed. This matters because the treatment algorithms differ. A general practitioner who sees three or four neuropathic pain patients per month may not stay current on guidelines the way a specialist who sees thirty per week does. Prescribing patterns reflect this: many commonly used neuropathic pain drugs are unlicensed for these specific indications, which creates both access barriers and insurance headaches.
When a drug is prescribed off-label, prior authorization requirements and formulary restrictions can delay or block treatment entirely. Take the example of a 70-year-old man with post-herpetic neuralgia following a shingles outbreak. His primary care doctor prescribes ibuprofen and acetaminophen — reasonable for many types of pain, but largely useless for neuropathic pain, which operates through entirely different mechanisms. Weeks pass. The pain does not improve. Eventually, a friend suggests he ask about gabapentin. He does, and his doctor agrees to try it. But the starting dose is too low, the titration too slow, and no one reassesses at the four-week mark. He gives up and resigns himself to living with the pain. This story repeats itself in primary care offices every day. Forty-five percent of neuropathic pain patients require at least two medications for adequate pain control, a level of polypharmacy management that demands more time, expertise, and follow-up than most primary care visits allow.
What the Opioid Crisis Changed — and What It Made Worse
The opioid epidemic reshaped how American physicians think about pain management, and for good reason. The over-prescribing of opioids caused enormous harm. But the course correction has had unintended consequences for neuropathic pain patients. As the American Academy of Family Physicians has documented, the opioid crisis paradoxically led to undertreatment of pain when physicians substituted gabapentinoids that may be less effective in individual cases. The pendulum swung from one imperfect tool to another, without landing on a more thoughtful middle ground. Strong opioids have an NNT of 4.3 for neuropathic pain — better than gabapentin at 7.2 or pregabalin at 7.7. This does not mean opioids are the answer.
Their risks, including dependence, respiratory depression, and cognitive impairment, are well-documented and particularly dangerous for older adults. But the blanket substitution of gabapentinoids for opioids in all pain patients, regardless of pain type, represents a failure of individualized medicine. A patient with severe post-surgical neuropathic pain who might have benefited from a short, carefully monitored course of a low-dose opioid instead receives gabapentin at a subtherapeutic dose and is told to give it time. The tradeoff here is not between good and bad. It is between two imperfect options, and the decision should be made on a case-by-case basis rather than by policy reflex. The comparison worth making is this: tricyclic antidepressants, with an NNT of 3.6, are actually the most effective drug class for neuropathic pain by the numbers. Yet they are prescribed far less than gabapentinoids, in part because of their cardiotoxicity risk in elderly patients and in part because gabapentin and pregabalin are perceived as safer and newer. For a younger patient with neuropathic pain and no cardiac history, a tricyclic might be the best first-line option — but it often is not even discussed.
Neuropathic Pain in Underserved Populations — An Invisible Crisis
Neuropathic pain does not distribute itself evenly across the global population. IASP’s 2026 Global Year initiative highlights that the condition disproportionately affects underserved populations through conditions like HIV-associated neuropathy, leprosy, trauma-related nerve injuries, and limb amputations. In many parts of the world, the drugs discussed in this article are either unavailable, unaffordable, or both. Population prevalence of neuropathic pain is estimated at 7 to 10 percent of adults overall, but that number rises to 20 to 30 percent in people with diabetes — a condition whose prevalence is itself climbing fastest in low- and middle-income countries. The warning here is that access to a diagnosis does not equal access to treatment.
Even in wealthy nations, insurance formularies, prior authorization requirements, and the off-label status of many neuropathic pain drugs create barriers. A patient might receive a correct diagnosis of painful diabetic neuropathy but find that their insurance requires them to fail on two cheaper medications before covering duloxetine. By the time they reach the third drug, months of inadequately treated pain have passed, sleep has deteriorated, mood has declined, and for older adults, cognitive function may have worsened. For patients with co-existing dementia, this cascade compounds an already fragile situation. Chronic uncontrolled pain is itself a risk factor for cognitive decline, creating a vicious cycle in which undertreated pain accelerates the very brain deterioration that makes pain management more difficult.
Why Combination Therapy Is Underused
Research published in Pain Medicine found that 45 percent of neuropathic pain patients require at least two medications for adequate pain control. Yet in practice, combination therapy is often a last resort rather than an early strategy. A patient might spend a year cycling through monotherapy trials — gabapentin alone, then pregabalin alone, then duloxetine alone — before anyone considers combining a gabapentinoid with an antidepressant or adding a topical agent like lidocaine patches.
The reluctance is partly about training and partly about complexity. Managing one drug’s titration schedule and side-effect profile is simpler than managing two. But for a patient who gets 20 percent relief from gabapentin and 15 percent from duloxetine individually, a carefully managed combination might push them past the threshold of meaningful benefit. The 2025 Lancet Neurology review confirmed that current treatments have limited efficacy as monotherapy, which should be read as an implicit argument for more aggressive combination strategies and integration of non-pharmacological approaches like neuromodulation — not as a reason to accept failure.
What Current Research Says About the Future
The most honest assessment of where neuropathic pain treatment stands in 2026 is this: the drugs have not gotten much better, but the understanding of why they fail has improved. The 2025 Lancet Neurology systematic review and meta-analysis re-evaluated both drug therapy and non-invasive neuromodulation, confirming the limited efficacy of pharmacotherapy while suggesting that neuromodulation techniques may offer additional benefit for some patients. The 2025 meta-analysis comparing pregabalin and gabapentin found no significant difference in efficacy between them, though pregabalin’s more predictable pharmacokinetics may make it easier to dose.
Neither of these findings represents a breakthrough, but together they point toward a future in which treatment is more personalized and less reliant on a single pill. For patients and caregivers navigating brain health alongside neuropathic pain, the practical takeaway is to push for specialist referral, ask about combination therapy early, and question any treatment plan that cycles through multiple drugs from the same class without considering alternatives. The 580 to 830 million people affected by neuropathic pain worldwide deserve better than a system that treats them with drugs statistically likely to fail, prescribed by clinicians who may not have the specialized training to optimize what little these drugs offer.
Conclusion
The reasons nerve pain patients never get the right drug are layered and reinforcing. The drugs themselves are mediocre, with the best available options failing more patients than they help. Side effects drive discontinuation within months. Primary care physicians, who manage the majority of these patients, often lack the specialized knowledge to optimize dosing, sequencing, and combination strategies. The opioid crisis pushed prescribing toward gabapentinoids by default rather than by individual assessment. And for underserved populations, access barriers compound clinical limitations.
None of this means treatment is hopeless. It means the current system requires patients and caregivers to be informed, persistent advocates. Request referral to a pain specialist or neurologist. Ask whether the dose has been fully optimized before switching drugs. Discuss combination therapy. Raise concerns about cognitive side effects explicitly, especially if dementia or cognitive impairment is already part of the picture. The gap between what neuropathic pain treatment could be and what it typically is remains wide — but it narrows considerably when patients know what questions to ask and refuse to accept “we’ve tried everything” after two drugs from the same class.
Frequently Asked Questions
What is the most effective drug for nerve pain?
By the numbers, tricyclic antidepressants like amitriptyline have the best efficacy data, with an NNT of 3.6. However, their side-effect profile — particularly the risk of cardiotoxicity — makes them unsuitable for many older adults. There is no single best drug; treatment must be matched to the individual patient’s medical history, age, and other medications.
Why does gabapentin not work for everyone with nerve pain?
Gabapentin has an NNT of 7.2, meaning approximately seven patients must be treated for one to achieve 50 percent pain relief. The drug works by modulating calcium channels involved in pain signaling, but neuropathic pain arises from diverse mechanisms — damaged nerve fibers, central sensitization, inflammatory pathways — and gabapentin only addresses some of them.
Should I see a specialist for nerve pain instead of my primary care doctor?
If your pain has not responded to one or two medications, or if you are experiencing significant side effects, a referral to a neurologist or pain specialist is reasonable. Most neuropathic pain patients are managed in primary care, and research shows considerable variation in treatment quality outside specialist settings.
Can nerve pain medications affect memory or thinking?
Yes. Gabapentinoids cause somnolence and cognitive dulling in a significant proportion of patients. Tricyclic antidepressants have anticholinergic properties linked to cognitive impairment, particularly in older adults. For anyone already experiencing memory concerns or early dementia, these side effects warrant a careful conversation with a physician about the risk-benefit balance.
How long should I try a nerve pain medication before deciding it does not work?
Most guidelines recommend a trial of four to eight weeks at an adequate dose. The key phrase is “adequate dose” — many patients are started on a low dose that is never titrated upward. If you have been on a low dose of gabapentin for three months with no improvement and no dose increase, the drug has not been fairly tested.
Is there anything new on the horizon for neuropathic pain treatment?
A 2025 Lancet Neurology systematic review confirmed the limited efficacy of current pharmacotherapy but found emerging evidence supporting non-invasive neuromodulation techniques. Research into more targeted drug therapies based on pain phenotyping — matching the specific mechanism of a patient’s nerve pain to the drug most likely to address it — is ongoing, though no breakthroughs have reached clinical practice as of early 2026.
